Shopping Cart
- Remove All
- Your shopping cart is currently empty
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively. PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $52 | In Stock | |
2 mg | $74 | In Stock | |
5 mg | $123 | In Stock | |
10 mg | $197 | In Stock | |
25 mg | $383 | In Stock | |
50 mg | $619 | In Stock | |
100 mg | $892 | In Stock | |
1 mL x 10 mM (in DMSO) | $135 | In Stock |
Description | PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively. PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials. |
Targets&IC50 | 3CLpro (SARS CoV-2):4 nM, 3CLpro (SARS CoV-1):0.27 nM |
Molecular Weight | 472.53 |
Formula | C24H32N4O6 |
Cas No. | 870153-29-0 |
Smiles | COc1cccc2[nH]c(cc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)CO |
Relative Density. | 1.264 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 250 mg/mL (529.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.